Sponsored / 9 Min Read

Emerging Biotech's Breakthrough in Pancreatic Cancer Trial Targets $1 Billion Market… (29) (33)

See why now may be the best time to start your research on RenovoRx Inc. (NASDAQ: RNXT).

Pioneering Change in Pancreatic Cancer Care (34)

Image Source (35)
Pancreatic cancer, often detected at an advanced stage, poses a formidable challenge for patients and doctors alike. Among these stages, stage 4, or metastatic pancreatic cancer, is particularly grim as it signifies the cancer’s spread to distant parts of the body, making it difficult to treat effectively.

Stage 4 pancreatic cancer, also known as metastatic pancreatic cancer, is marked by cancer cells spreading to vital organs. Survival rates at this stage are disheartening, ranging from 2% to 12%, with factors like age influencing outcomes.

Given the limited chances of a cure, the focus shifts to palliative care, aiming to alleviate pain, improve comfort, and address emotional needs, ultimately enhancing patients’ quality of life.

Despite the challenges, medical research strives to offer hope.

RenovoRx, Inc. (Nasdaq: RNXT) stands at the forefront, pioneering treatments like the Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. Though currently focused on locally advanced pancreatic cancer, RenovoRx’s dedication may herald hope for stage 4 patients in the future.
Image Source (33)
Keep reading to see why RenovoRx, Inc. (Nasdaq: RNXT) needs to be at the top of your daily watch-list.

7 Reasons Why RenovoRx, Inc. (Nasdaq: RNXT) Could Be Poised For Significant Upside Potential in 2024.

1

Analyst Coverage. Generally speaking, when it comes to Wall Street, a target is a range at which an analyst believes a stock to be fairly valued relative to its projected and historical earnings. When an analyst assigns a target for a stock, they generally expect the stock price to rise or fall accordingly.(12) According to financial news portal TipRanks, RenovoRx, Inc. (Nasdaq: RNXT) received a $7 target from Scott Henry of I-Banking Firm, Roth MKM. (31) This would indicate an upside potential of over 1,219% from the company's 52-week low of $.5306 set on 12/6/2023. (2)

2

Extremely Low-Float. Market participants typically consider a float of 10-to-20 million shares as a low float. Some larger corporations have very high floats in the billions.(3) According to FinViz.com RenovoRx, Inc. (Nasdaq: RNXT) has less than 8.9M shares available in float as of 12/20/2023.(4) A low-float stock can make significant moves due to volatility from so few shares being available(3), so this could be an interesting situation to watch closely.

3

Groundbreaking TAMP™ Therapy Platform. The Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, currently in a Phase III clinical trial for pancreatic cancer, represents a potential game-changer in cancer treatment. The platform's precision in delivering targeted therapy, as demonstrated by positive interim analysis results, indicates its potential to enhance treatment outcomes and reduce adverse events. RenovoRx, Inc. (Nasdaq: RNXT) is at the forefront of this innovative approach. (29)

4

Strategic Collaboration with Imugene. RenovoRx, Inc. (Nasdaq: RNXT)’s collaboration with Imugene Ltd to explore oncolytic virus therapy using the TAMP™ platform not only validates its technology but also expands its application from chemotherapy to immunotherapy. This strategic partnership opens doors to innovative treatment approaches and positions RenovoRx, Inc. (Nasdaq: RNXT) as a player in the evolving field of cancer immunotherapy. (29)

5

Financial Stability and Responsibility. In terms of financial performance, the company's commitment to advancing cancer research while maintaining fiscal responsibility is evident. With a cash position of $3.2 million as of September 30, 2023, and improved net loss figures, RenovoRx, Inc. (Nasdaq: RNXT) has demonstrated its ability to manage expenses efficiently, instilling confidence in its long-term prospects. (29)

6

Promising Clinical Trial Progress: The successful interim analysis of the Phase III TIGeR-PaC clinical trial, which aims for a 6-month Overall Survival (OS) benefit, is a significant milestone. The Data Monitoring Committee's recommendation to continue the trial indicates the potential effectiveness of RenovoRx, Inc. (Nasdaq: RNXT)’s TAMP™ platform in treating pancreatic cancer. Industry stakeholders may see value in the company's progress toward meeting primary and secondary endpoints. (29)

7

Visionary Leadership. CEO Shaun Bagai's commitment to improving cancer care and delivering novel targeted combination therapies is evident in RenovoRx, Inc. (Nasdaq: RNXT)’s mission. His leadership and the company's focus on transformative solutions position RenovoRx as a player with a vision to alter the current paradigm of oncology care. (29)

RenovoRx, Inc. (Nasdaq: RNXT) Receives $7.00 Target, Which Could Indicate an Upside Potential of Over 1,219% From its 52-Week Low...(31)(2)

Image Source 12

Generally speaking, when it comes to Wall Street, a target is a range at which an analyst believes a stock to be fairly valued relative to its projected and historical earnings. When an analyst raises their target for a stock, they generally expect the stock price to rise.(12)

A target is an analyst’s projection of a security’s future range. Targets can pertain to all types of securities, from complex financial products to stocks and bonds. When setting a stock’s target, an analyst is trying to determine what the stock is worth and what the range could be in 12 or 18 months. Ultimately, targets depend on the valuation of the company that’s issuing the stock.(12)

Analysts generally publish their targets in research reports on specific companies, along with their buy, sell, and hold recommendations for the company’s stock. Stock targets are often quoted in the financial news media.(12)

And this time, Benzinga.com(30) and TipRanks(31) are both indicating that RenovoRx, Inc. (Nasdaq: RNXT) has received analyst coverage from I-Banking Firm, Roth MKM. TipRanks is reporting that RenovoRx, Inc. (Nasdaq: RNXT) has been assigned a $7.00 target by analyst Scott Henry of Roth MKM. This would indicate an upside potential of over 1,219% from RenovoRx, Inc. (Nasdaq: RNXT)’s 52-week low of $.5306 set on 12/6/2023, according to Barchart.com’s pricing history. (2)

Chart Source (24)

Looking at RenovoRx, Inc.’s (Nasdaq: RNXT)’s chart above you can see what a 1,219% move would look like…

That isn’t to say a move like that is certain, but an analyst’s target is something important to take into account.

Then taking a deeper dive into StockCharts.com (below), you’ll see the following moving averages:


Chart Source (32)

  • – Daily Average Price: $.71 as of 12/20/2023 (which would suggest over 885% in upside potential to the target set by Scott Henry of Roth MKM) (31)(2)
  • – 50 Day Moving Average $.89
  • – 100 Day Moving Average $1.24
  • – 200 Day Moving Average $1.89
  • – 52-Week Low: $.5306 according to Barchart.com.(2)
  • – 52-Week High $5.74 according to Barchart.com. (2)
  • – Roth MKM Target: $7.00 (31)

Keep reading to see why RenovoRx, Inc.’s (Nasdaq: RNXT) deserves a top spot on your daily watch list.

RenovoRx, Inc. (Nasdaq: RNXT) Has an Extreme Low-Float.(3)(4

6

Image Source (18)

Low float stocks refer to the securities that remain after a company’s stock has been issued to its controlling investors — meaning there are relatively few shares for the public to buy.(3)

Market participants typically consider a float of 10-to-20 million shares as a low float. Some larger corporations have very high floats in the billions.(3)

Companies with a low float frequently have a large portion of their equity held by controlling investors such as directors and employees, which leaves only a tiny percentage of the stock available for public trading. (3)

That limited supply can cause dramatic price swings if demand changes quickly.(3)

Because low-float stocks have fewer shares available, market participants may have difficulty finding shares available. (3)

Low float stocks have the potential to present significant swings as active market participants take notice.(3)

RenovoRx, Inc. (Nasdaq: RNXT) has less than 8.9M shares available in its float (as of 12/20/2023) according to FinViz.com.(4) A low-float stock can make significant moves due to volatility from so few shares being available(3), so this could be one interesting situation to watch closely.

RenovoRx, Inc. (Nasdaq: RNXT) is also considered a nano-cap. In general, nano-cap companies have market capitalizations of less than $50 million.(5) Because nano-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly. (6)

As of 12/20/2023, RenovoRx, Inc. (Nasdaq: RNXT) has a market cap of approximately $7.82M according to MarketWatch.com. (22)

Which is why things could get very interesting and also why you need to start your research on RenovoRx, Inc. (Nasdaq: RNXT).

Could RenovoRx, Inc. (Nasdaq: RNXT) Strengthens Its Intellectual Property (IP) Portfolio with Their 8th US Patent.(7)

Image Source (33)

RenovoRx, Inc. (Nasdaq: RNXT) Strengthens Its Intellectual Property (IP) Portfolio with Their 8th US Patent. bolstering the 7 years of Post-Approval Market Exclusivity That they Currently have with their Lead Oncology Product Candidate, RenovoGem™, Through the Orphan Drug Designation granted by the FDA for their first two indications…(7)

8

Image Source (19)

RenovoRx, Inc. (Nasdaq: RNXT) has strengthened its Intellectual Property (IP) portfolio with the issuance of its eighth US patent. This patent, numbered 11,541,211, encompasses methods for treating cholangiocarcinoma (bile duct cancer) by selectively delivering therapeutic agents into targeted areas of the bile duct. RenovoRx’s CEO, Shaun Bagai, emphasized the significance of this new addition to their IP portfolio, which now comprises eight US method and device patents, one EU delivery system patent, and eight pending patents across the US, EU, and Asia. (7)

This latest patent also reinforces the company’s seven years of post-approval market exclusivity for their lead oncology product candidate, RenovoGem™, through FDA-granted Orphan Drug designation for their first two indications: Locally Advanced Pancreatic Cancer (LAPC) and Extrahepatic Cholangiocarcinoma (eCCA) or Bile Duct Cancer.

Image Source (33)

The first indication, LAPC, addresses one of the deadliest cancers with a grim 5-year overall survival rate of 5-10%. RenovoRx, Inc. (Nasdaq: RNXT)’s Orphan Designation for this indication aims to improve treatment outcomes for the thousands of Americans diagnosed with pancreatic cancer each year.

The second indication, eCCA or Bile Duct Cancer, also presents a dismal prognosis, and no standard of care has been established due to treatment toxicity. RenovoRx, Inc. (Nasdaq: RNXT)’s innovative approach, protected by its expanding IP portfolio, holds promise for patients facing this challenging diagnosis. (7)

Image Source 9

How Patients and Physicians Experience RenovoTAMPTherapy (9)

RenovoRx, Inc. (Nasdaq: RNXT) Employs De-risked Small Molecule Chemotherapy Drugs First Drug Candidate: Intra-Arterial Gemcitabine. (9)

Gemcitabine(9)

RenovoGem (Intra-arterial Gemcitabine + RenovoCath) (9)
About RenovoRx, Inc. (Nasdaq: RNXT) (7)

RenovoRx is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. The company’s mission is to lead a revolution in oncology therapy by delivering its innovative and targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors.

The proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform aims to avoid the harsh side effects typical of the current standard of care, thus improving patient well-being and extension of life so more time may be enjoyed with loved ones.

10

Image Source (9)

RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. (7)

RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and its patented delivery system, RenovoCath®, and is regulated by the FDA.(7)

Image Source (20)

RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and its patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC).

Image Source (9)

RenovoGem is currently being studied in the Phase III TIGeR-PaC trial for the treatment of LAPC.(7)

Image Source (9)

RenovoRx’s patent portfolio for its therapy platform and product candidates includes eight issued U.S. patents, one issued European patent, and several additional patents pending in the US, EU and Asia.

RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer (cholangiocarcinoma). (7)

RenovoRx, Inc. (Nasdaq: RNXT) Highlights & Pipeline Overview(33)

RenovoRx, Inc. Highlights (33)

Potential Upcoming Milestones(33)

Image Source (33)

Phase III Trial News: RenovoRx, Inc. (Nasdaq: RNXT)’s Innovative Therapy Platform Shows Promise in Pancreatic Cancer Treatment Study.(25)

Image Source (26)
RenovoRx, Inc. (Nasdaq: RNXT) has initiated patient enrollment for its pivotal Phase III TIGeR-PaC clinical trial at the University of Texas Southwestern Medical Center. The trial focuses on RenovoGem™, a targeted combination therapy for pancreatic cancer, utilizing RenovoRx’s proprietary TAMP™ therapy platform for improved intra-arterial gemcitabine chemotherapy delivery. (25) Promising interim data analysis has shown a 60% improvement in median overall survival and a significant 65% reduction in side effects compared to standard treatment. Dr. Salwan Al Mutar, Principal Investigator, highlighted the significance of targeted, intra-arterial chemotherapy for pancreatic cancer patients. Dr. Ramtin Agah, RenovoRx’s CMO, praised UT Southwestern’s involvement, emphasizing the shared vision of enhancing cancer patient outcomes. UT Southwestern Medical Center joins other clinical trial sites across the U.S. in enrolling patients for this groundbreaking study, offering hope for improved pancreatic cancer treatment options. (25)

RenovoRx, Inc. (Nasdaq: RNXT) Reports Q3 2023 Financial Results and Advances in Cancer Care… (29)

Image Source (36)
The company continues to make significant strides in its mission to revolutionize cancer treatment, notably through its pioneering Trans-Arterial Micro-Perfusion (TAMP™) platform and strategic collaborations.

TAMP™ Therapy Platform: A Potential Game-Changer (29)
At the heart of RenovoRx’s recent successes lies its proprietary TAMP™ therapy platform. The TAMP™ platform, currently undergoing a Phase III clinical trial for the treatment of Pancreatic Cancer, has generated excitement within the medical community. Notably, an interim analysis conducted in March 2023 received a favorable recommendation from the Data Monitoring Committee, paving the way for the trial’s continuation.

The Phase III TIGeR-PaC clinical trial prespecifies a primary endpoint of a 6-month Overall Survival (OS) benefit, accompanied by secondary endpoints focused on reducing adverse events compared to standard care. Dr. Michael J. Pishvaian, Principal Investigator of TIGeR-PaC, showcased the potential of the TAMP™ therapy platform at the Global Summit on Gastrointestinal Malignancies. His presentation highlighted the platform’s precision in delivering targeted cancer treatment, promising increased safety, tolerance, and efficacy.

Collaboration with Imugene: Expanding Horizons (29)
Image Source (33)
RenovoRx’s strategic collaboration with Imugene Ltd (ASX: IMU) underscores its commitment to broadening the scope of cancer care. This partnership not only validates the TAMP™ platform but also extends its use from chemotherapy to immunotherapy. By exploring the delivery of oncolytic virus therapy using TAMP™, RenovoRx aims to enhance treatment options and redefine cancer care paradigms.

Financial Performance (29)
RenovoRx’s financial results for the third quarter ended September 30, 2023, highlight its dedication to advancing cancer research and development while maintaining fiscal responsibility:

Cash Position: As of September 30, 2023, RenovoRx held $3.2 million in cash and cash equivalents, ensuring the company’s ability to continue its vital work.

R&D Expenses: Research and development expenses totaled $1.6 million for the quarter, reflecting ongoing Phase III clinical trial costs and increased employee-related benefits expenses. This investment in research underscores RenovoRx’s commitment to pushing the boundaries of cancer treatment.

G&A Expenses: General and administrative expenses remained stable at $1.3 million for the third quarter of 2023 compared to the same period last year. While employee and related benefits costs increased, this was offset by decreased insurance expenses and a reallocation of administrative expenses to research and development.

Shares Outstanding: As of September 30, 2023, RenovoRx had 10,693,080 shares of common stock outstanding.

CEO’s Vision (29)
Shaun Bagai, CEO of RenovoRx, reaffirmed the company’s commitment to improving cancer care, stating, “We remain focused on our core mission to improve the lives of patients diagnosed with difficult-to-treat cancers by delivering novel targeted combination therapies that have the potential to alter the current paradigm of oncology care.” (29)

RenovoRx’s progress in its pivotal Phase III TIGeR-PaC study, its partnership with Imugene, and its financial stability are all indicative of a company poised to make a lasting impact in the field of oncology. As it continues to push the boundaries of cancer treatment, RenovoRx holds great promise for patients, offering new hope for those facing challenging diagnosis. (29)

Meet the Management Team Leading RenovoRx, Inc. (NASDAQ: RNXT) Into 2023

GET RED-HOT STOCK TIPS DELIVERED DIRECT TO YOUR INBOX:

7 Reasons Why RenovoRx, Inc. (Nasdaq: RNXT) Could Be Poised For Significant Upside Potential in 2023.

1

Analyst Coverage. Generally speaking, when it comes to Wall Street, a target is a range at which an analyst believes a stock to be fairly valued relative to its projected and historical earnings. When an analyst assigns a target for a stock, they generally expect the stock price to rise or fall accordingly.(12) According to financial news portal TipRanks, RenovoRx, Inc. (Nasdaq: RNXT) received a $7 target from Scott Henry of I-Banking Firm, Roth MKM. (31) This would indicate an upside potential of over 1,219% from the company's 52-week low of $.5306 set on 12/6/2023. (2)

2

Extremely Low-Float. Market participants typically consider a float of 10-to-20 million shares as a low float. Some larger corporations have very high floats in the billions.(3) According to FinViz.com RenovoRx, Inc. (Nasdaq: RNXT) has less than 8.9M shares available in float as of 12/20/2023.(4) A low-float stock can make significant moves due to volatility from so few shares being available(3), so this could be an interesting situation to watch closely.

3

Groundbreaking TAMP™ Therapy Platform. The Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, currently in a Phase III clinical trial for pancreatic cancer, represents a potential game-changer in cancer treatment. The platform's precision in delivering targeted therapy, as demonstrated by positive interim analysis results, indicates its potential to enhance treatment outcomes and reduce adverse events. RenovoRx, Inc. (Nasdaq: RNXT) is at the forefront of this innovative approach. (29)

4

Strategic Collaboration with Imugene. RenovoRx, Inc. (Nasdaq: RNXT)’s collaboration with Imugene Ltd to explore oncolytic virus therapy using the TAMP™ platform not only validates its technology but also expands its application from chemotherapy to immunotherapy. This strategic partnership opens doors to innovative treatment approaches and positions RenovoRx, Inc. (Nasdaq: RNXT) as a player in the evolving field of cancer immunotherapy. (29)

5

Financial Stability and Responsibility. In terms of financial performance, the company's commitment to advancing cancer research while maintaining fiscal responsibility is evident. With a cash position of $3.2 million as of September 30, 2023, and improved net loss figures, RenovoRx, Inc. (Nasdaq: RNXT) has demonstrated its ability to manage expenses efficiently, instilling confidence in its long-term prospects. (29)

6

Promising Clinical Trial Progress: The successful interim analysis of the Phase III TIGeR-PaC clinical trial, which aims for a 6-month Overall Survival (OS) benefit, is a significant milestone. The Data Monitoring Committee's recommendation to continue the trial indicates the potential effectiveness of RenovoRx, Inc. (Nasdaq: RNXT)’s TAMP™ platform in treating pancreatic cancer. Industry stakeholders may see value in the company's progress toward meeting primary and secondary endpoints. (29)

7

Visionary Leadership. CEO Shaun Bagai's commitment to improving cancer care and delivering novel targeted combination therapies is evident in RenovoRx, Inc. (Nasdaq: RNXT)’s mission. His leadership and the company's focus on transformative solutions position RenovoRx as a player with a vision to alter the current paradigm of oncology care. (29)

Source 1: https://www.maximgrp.com/wp-content/uploads/2023/01/Research-Universe_1.13.23.pdf Source 2: https://www.barchart.com/stocks/quotes/RNXT/price-history/historical Source 3: https://www.sofi.com/learn/content/understanding-low-float-stocks/ Source 4: https://finviz.com/quote.ashx?t=RNXT&p=d Source 5: https://www.investopedia.com/terms/n/nanocap.asp Source 6: https://www.benzinga.com/money/best-nano-cap-stocks Source 7: https://finance.yahoo.com/news/renovorx-strengthens-intellectual-property-ip-133000702.html Source 8: https://finance.yahoo.com/news/renovorx-announces-acceptance-four-clinical-133000761.html Source 9: https://d1io3yog0oux5.cloudfront.net/_97522d4a6d680490bdfeee4955fd3b2a/renovorx/db/2223/20908/pdf/RNXT+IR+Deck_2023_05-04.pdf Source 10: https://pbs.twimg.com/media/EDrTVVFXYAA5EFj.jpg Source 11: https://www.forbes.com/advisor/wp-content/uploads/2021/04/nyse.jpg Source 12: https://www.investopedia.com/terms/p/pricetarget.asp Source 13: https://www.maximgrp.com/team_members/jason-mccarthy-ph-d/ Source 14: https://www.maximgrp.com/about-us/ Source 15: https://www.linkedin.com/posts/maxim-group_maxim-group-2022-year-end-review-activity-7019388769157967872-lTRd/?originalSubdomain=gr Source 16: https://schrts.co/zAGgvMtJ Source 17: https://www.thebalancemoney.com/triangle-chart-patterns-and-day-trading-strategies-4111224 Source 18: https://investmentu.com/low-float-stocks/ Source 19: https://www.raps.org/RAPS/media/news-images/news-images/FDA-Logo.jpg Source 20: https://renovorx.com/wp-content/uploads/2021/05/square-catheter.jpg Source 21: https://pancan.org/news/five-year-pancreatic-cancer-survival-rate-increases-to-12/ Source 22: https://www.marketwatch.com/investing/stock/rnxt?mod=search_symbol Source 23: https://schrts.co/RptJryQN Source 24: https://www.otcmarkets.com/stock/RNXT/overview(as of 11/14/2023) Source 25: https://finance.yahoo.com/news/renovorx-initiates-patient-enrollment-university-123000346.html Source 26: https://renovorx.com/wp-content/uploads/2019/11/NewBeautyImage-1024×576.jpg Source 29: https://finance.yahoo.com/news/renovorx-reports-third-quarter-2023-133000876.html Source 30: https://www.benzinga.com/quote/RNXT/analyst-ratings Source 31: https://www.tipranks.com/stocks/rnxt/forecast Source 32: https://schrts.co/efZPgnxC Source 33: https://d1io3yog0oux5.cloudfront.net/_7432738ba51df07b35ca397236ce22b0/renovorx/db/2223/20930/pdf/RNXT+IR+Deck_2023-11-06-2023-2.pdf Source 34: https://www.verywellhealth.com/stage-4-pancreatic-cancer-5093642 Source 35: https://www.roswellpark.org/sites/default/files/2021-07/adobestock_181431116.jpg Source 36: https://seekingalpha.com/symbol/RNXT

GET RED-HOT NEWS DELIVERED RIGHT TO YOUR INBOX.

Getting the Right News Before Everyone Else Does, is FREE…